[et_pb_section fb_built=»1″ fullwidth=»on» _builder_version=»4.21.0″ _module_preset=»default» background_image=»https://neuroexeltis.mx/wp-content/uploads/2023/06/shutterstock_1380568544-scaled.jpg» background_repeat=»repeat» custom_margin=»24px||||false|false» global_colors_info=»{}»][et_pb_fullwidth_header title=»Literatura médica epilepsia» text_orientation=»center» _builder_version=»4.17.6″ _module_preset=»default» title_font=»|700|||||||» title_text_align=»center» title_font_size=»50px» background_enable_color=»off» title_text_shadow_style=»preset5″ text_shadow_style=»preset5″ global_colors_info=»{}»][/et_pb_fullwidth_header][/et_pb_section][et_pb_section fb_built=»1″ _builder_version=»4.17.6″ _module_preset=»default» custom_margin=»24px||||false|false» global_colors_info=»{}»][et_pb_row column_structure=»1_4,1_4,1_4,1_4″ use_custom_gutter=»on» gutter_width=»2″ make_equal=»on» _builder_version=»4.17.6″ _module_preset=»default» width=»90%» max_width=»1316px» module_alignment=»center» min_height=»319.7px» custom_margin=»16px|auto||auto|false|false» global_colors_info=»{}»][et_pb_column type=»1_4″ _builder_version=»4.17.6″ _module_preset=»default» global_colors_info=»{}»][et_pb_blurb title=»Global, regional, and national burden of epilepsy, 1990–2016: a systematic analysis » url=»https://neuroexeltis.mx/literatura/GBepilepsy1990_2016.pdf» url_new_window=»on» image=»https://neuroexeltis.mx/wp-content/uploads/2022/08/Global-burden-epilepsy-1990-2016.png» image_icon_width=»90%» _builder_version=»4.19.5″ _module_preset=»default» header_level=»h5″ header_font=»|600|||||||» body_text_align=»justify» body_font_size=»12px» text_orientation=»center» link_option_url_new_window=»on» border_width_all_image=»5px» border_color_all_image=»#B3B3B3″ box_shadow_style_image=»preset6″ global_colors_info=»{}»]

Seizures and their consequences contribute to the burden of epilepsy because they can cause health loss (premature mortality and residual disability). Data on the burden of epilepsy are needed for health-care planning and resource allocation.

[/et_pb_blurb][/et_pb_column][et_pb_column type=»1_4″ _builder_version=»4.17.6″ _module_preset=»default» global_colors_info=»{}»][et_pb_blurb title=»Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis» url=»https://neuroexeltis.mx/literatura/GBneurological1990_2016.pdf» url_new_window=»on» image=»https://neuroexeltis.mx/wp-content/uploads/2022/08/Globalburdenneurological_1990-2016.png» image_icon_width=»83%» _builder_version=»4.21.0″ _module_preset=»default» header_level=»h5″ header_font=»|600|||||||» body_text_align=»justify» body_font_size=»12px» text_orientation=»center» link_option_url_new_window=»on» border_width_all_image=»5px» border_color_all_image=»#B3B3B3″ box_shadow_style_image=»preset6″ global_colors_info=»{}»]

Neurological disorders are increasingly recognised as major causes of death and disability worldwide. The aim of this analysis from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2016 is to provide the most comprehensive and up-to-date estimates of the global, regional, and national burden from neurological disorders.

[/et_pb_blurb][/et_pb_column][et_pb_column type=»1_4″ _builder_version=»4.17.6″ _module_preset=»default» global_colors_info=»{}»][et_pb_blurb title=»The Epidemiology of Epilepsy» url=»https://www.karger.com/Article/Pdf/503831″ url_new_window=»on» image=»https://neuroexeltis.mx/wp-content/uploads/2022/08/epidemiologyEpilepsy2020.png» image_icon_width=»85%» _builder_version=»4.21.0″ _module_preset=»default» header_level=»h5″ header_font=»|600|||||||» body_text_align=»justify» body_font_size=»12px» text_orientation=»center» link_option_url_new_window=»on» border_width_all_image=»5px» border_color_all_image=»#B3B3B3″ box_shadow_style_image=»preset6″ global_colors_info=»{}»]

Seizures and their consequences Epilepsy is a chronic disease of the brain characterized by an enduring (i.e., persisting) predisposition to generate seizures, unprovoked by any immediate central nervous system insult, and by the neurobiologic, cognitive, psychologi- cal, and social consequences of seizure recurrences

[/et_pb_blurb][/et_pb_column][et_pb_column type=»1_4″ _builder_version=»4.17.6″ _module_preset=»default» global_colors_info=»{}»][et_pb_blurb title=»Drug Resistance in Epilepsy: Clinical Impact, Potential Mechanisms, and New Innovative Treatment Options» url=»https://pharmrev.aspetjournals.org/content/pharmrev/72/3/606.full.pdf» url_new_window=»on» image=»https://neuroexeltis.mx/wp-content/uploads/2022/08/DrugresistenceEpilepsy2020.png» image_icon_width=»85%» _builder_version=»4.19.5″ _module_preset=»default» header_level=»h5″ header_font=»|600|||||||» body_text_align=»justify» body_font_size=»12px» text_orientation=»center» link_option_url_new_window=»on» border_width_all_image=»5px» border_color_all_image=»#B3B3B3″ box_shadow_style_image=»preset6″ global_colors_info=»{}»]

Epilepsy is a chronic neurologic disorder that affects over 70 million people worldwide. Despite the availability of over 20 antiseizure drugs (ASDs) for symptomatic treatment of epileptic seizures, about one-third of patients with epilepsy have seizures refractory to pharmacotherapy.

[/et_pb_blurb][/et_pb_column][/et_pb_row][et_pb_row column_structure=»1_4,1_4,1_4,1_4″ use_custom_gutter=»on» gutter_width=»2″ make_equal=»on» _builder_version=»4.17.6″ _module_preset=»default» width=»90%» max_width=»1316px» module_alignment=»center» min_height=»319.7px» custom_margin=»16px|auto||auto|false|false» global_colors_info=»{}»][et_pb_column type=»1_4″ _builder_version=»4.17.6″ _module_preset=»default» global_colors_info=»{}»][et_pb_blurb title=»Benzodiazepines in the Management of Seizures and Status Epilepticus: A Review of Routes of Delivery, Pharmacokinetics, Efficacy, and Tolerability» url=»https://neuroexeltis.mx/literatura/BenzodiazepinesManagementSeizuresStatus.pdf» url_new_window=»on» image=»https://neuroexeltis.mx/wp-content/uploads/2023/07/Benzodiazepines2022.png» image_icon_width=»90%» _builder_version=»4.21.0″ _module_preset=»default» header_level=»h5″ header_font=»|600|||||||» body_text_align=»justify» body_font_size=»12px» text_orientation=»center» link_option_url_new_window=»on» border_width_all_image=»5px» border_color_all_image=»#B3B3B3″ box_shadow_style_image=»preset6″ global_colors_info=»{}»]

Status epilepticus (SE) is an acute, life-threatening medical condition that requires immediate, effective therapy. Therefore, the acute care of prolonged seizures and SE is a constant challenge for healthcare professionals, in both the pre-hospital and the in-hospital settings. Benzodiazepines (BZDs) are the first-line treatment for SE worldwide due to their efficacy, tolerability, and rapid onset of action.

[/et_pb_blurb][/et_pb_column][et_pb_column type=»1_4″ _builder_version=»4.17.6″ _module_preset=»default» global_colors_info=»{}»][et_pb_blurb title=»First line management of prolonged convulsive seizures in children and adults: good practice points» url=»https://neuroexeltis.mx/literatura/Firstline_manage_prol_convulsive_seizures.pdf» url_new_window=»on» image=»https://neuroexeltis.mx/wp-content/uploads/2023/07/2013_fristline.png» image_icon_width=»83%» _builder_version=»4.21.0″ _module_preset=»default» header_level=»h5″ header_font=»|600|||||||» body_text_align=»justify» body_font_size=»12px» text_orientation=»center» link_option_url_new_window=»on» border_width_all_image=»5px» border_color_all_image=»#B3B3B3″ box_shadow_style_image=»preset6″ global_colors_info=»{}»]

Over the past decades, it has become clear that the most efficient way to prevent status epilepticus is to stop the seizure as fast as possible, and early treatment of prolonged convulsive seizures has become an integral part of the overall treatment strategy in epilepsy. Benzodiazepines are the first choice drugs to be used as emergency medication.

[/et_pb_blurb][/et_pb_column][et_pb_column type=»1_4″ _builder_version=»4.17.6″ _module_preset=»default» global_colors_info=»{}»][/et_pb_column][et_pb_column type=»1_4″ _builder_version=»4.17.6″ _module_preset=»default» global_colors_info=»{}»][/et_pb_column][/et_pb_row][et_pb_row _builder_version=»4.21.0″ _module_preset=»default» custom_margin=»0px||||false|false» hover_enabled=»0″ sticky_enabled=»0″][et_pb_column _builder_version=»4.21.0″ _module_preset=»default» type=»4_4″][et_pb_contact_form email=»contacto@exeltis.mx» title=»Solicitud de Artículos en texto completo» use_redirect=»on» redirect_url=»https://neuroexeltis.mx/literatura-medica/» success_message=»Su solicitud ha sido enviada» _builder_version=»4.21.0″ _module_preset=»default» _unique_id=»afdcd836-4ed8-4333-9c5e-37d849977887″ hover_enabled=»0″ global_colors_info=»{}» theme_builder_area=»post_content» sticky_enabled=»0″][et_pb_contact_field field_id=»Name» field_title=»Nombre» _builder_version=»4.16″ global_colors_info=»{}» button_text_size__hover_enabled=»off» button_one_text_size__hover_enabled=»off» button_two_text_size__hover_enabled=»off» button_text_color__hover_enabled=»off» button_one_text_color__hover_enabled=»off» button_two_text_color__hover_enabled=»off» button_border_width__hover_enabled=»off» button_one_border_width__hover_enabled=»off» button_two_border_width__hover_enabled=»off» button_border_color__hover_enabled=»off» button_one_border_color__hover_enabled=»off» button_two_border_color__hover_enabled=»off» button_border_radius__hover_enabled=»off» button_one_border_radius__hover_enabled=»off» button_two_border_radius__hover_enabled=»off» button_letter_spacing__hover_enabled=»off» button_one_letter_spacing__hover_enabled=»off» button_two_letter_spacing__hover_enabled=»off» button_bg_color__hover_enabled=»off» button_one_bg_color__hover_enabled=»off» button_two_bg_color__hover_enabled=»off» theme_builder_area=»post_content»][/et_pb_contact_field][et_pb_contact_field field_id=»Email» field_title=»Dirección de correo electrónico» field_type=»email» _builder_version=»4.16″ global_colors_info=»{}» button_text_size__hover_enabled=»off» button_one_text_size__hover_enabled=»off» button_two_text_size__hover_enabled=»off» button_text_color__hover_enabled=»off» button_one_text_color__hover_enabled=»off» button_two_text_color__hover_enabled=»off» button_border_width__hover_enabled=»off» button_one_border_width__hover_enabled=»off» button_two_border_width__hover_enabled=»off» button_border_color__hover_enabled=»off» button_one_border_color__hover_enabled=»off» button_two_border_color__hover_enabled=»off» button_border_radius__hover_enabled=»off» button_one_border_radius__hover_enabled=»off» button_two_border_radius__hover_enabled=»off» button_letter_spacing__hover_enabled=»off» button_one_letter_spacing__hover_enabled=»off» button_two_letter_spacing__hover_enabled=»off» button_bg_color__hover_enabled=»off» button_one_bg_color__hover_enabled=»off» button_two_bg_color__hover_enabled=»off» theme_builder_area=»post_content»][/et_pb_contact_field][et_pb_contact_field field_id=»Message» field_title=»Escriba aqui la(s) referencias» field_type=»text» fullwidth_field=»on» _builder_version=»4.21.0″ global_colors_info=»{}» button_text_size__hover_enabled=»off» button_one_text_size__hover_enabled=»off» button_two_text_size__hover_enabled=»off» button_text_color__hover_enabled=»off» button_one_text_color__hover_enabled=»off» button_two_text_color__hover_enabled=»off» button_border_width__hover_enabled=»off» button_one_border_width__hover_enabled=»off» button_two_border_width__hover_enabled=»off» button_border_color__hover_enabled=»off» button_one_border_color__hover_enabled=»off» button_two_border_color__hover_enabled=»off» button_border_radius__hover_enabled=»off» button_one_border_radius__hover_enabled=»off» button_two_border_radius__hover_enabled=»off» button_letter_spacing__hover_enabled=»off» button_one_letter_spacing__hover_enabled=»off» button_two_letter_spacing__hover_enabled=»off» button_bg_color__hover_enabled=»off» button_one_bg_color__hover_enabled=»off» button_two_bg_color__hover_enabled=»off» theme_builder_area=»post_content»][/et_pb_contact_field][/et_pb_contact_form][/et_pb_column][/et_pb_row][/et_pb_section]